Comparison of antibodies that mediate HIV type 1 gp120 antibody-dependent cell-mediated cytotoxicity in asymptomatic HIV type 1-positive men and women

AIDS Research and Human Retroviruses

Volumn 30, Issue 1, 2014, Pages 50-57

  Mata, Mariana M ^a   Iwema, Joyce R ^a   Dell, Shanna ^b   Neems, Leslie ^c   Jamieson, Beth D ^d   Phair, John ^e   Cohen, Mardge H ^f   Anastos, Kathryn ^g   Baum, Linda L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BELOIT COLLEGE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASYMPTOMATIC INFECTION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD; YOUNG ADULT; ASYMPTOMATIC INFECTIONS; BLOOD; CYTOTOXICITY TEST; DISEASE COURSE; IMMUNOLOGY; VIROLOGY;

ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ASYMPTOMATIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE PROGRESSION; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 84891765379     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0377     Document Type: Article

References (36)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
2. Bonsignori M, Pollara J, Moody MA, et al.: Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012;86(21): 11521-11532.
3. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366(14):1275-1286.
4. Yoshida R, Tazawa H, Hashimoto Y, et al.: Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. Cancer Immunol Immunother 2012;61(11):1905-1916.
5. Moldt B, Shibata-Koyama M, Rakasz EG, et al.: A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012;86(11):6189-6196.
6. Ferrari G, Pollara J, Kozink D, et al.: An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibodydependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011;85(14):7029-7036.
7. Alpert MD, Harvey JD, Lauer WA, et al.: ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012;8(8):e1002890.
8. Mabuka J, Nduati R, Odem-Davis K, Peterson D, and Overbaugh J: HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012;8(6):e1002739.
9. Johansson SE, Rollman E, Chung AW, et al.: NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 2011;24(5):359-368.
10. Chung AW, Isitman G, Navis M, et al.: Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011;108(18): 7505-7510.
11. Chung AW, Navis M, Isitman G, et al.: Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 2011;24(2):171-175.
12. Chung AW, Navis M, Isitman G, et al.: Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011;58(2):127-131.
13. Forthal DN, Landucci G, Haubrich R, et al.: Antibodydependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999;180(4):1338-1341.
14. Baum LL, Cassutt KJ, Knigge K, et al.: HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157(5): 2168-2173.
15. Nag P, Kim J, Sapiega V, et al.: Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 2004;190(11):1970-1978.
16. HIV-1 subtypes: Implications for epidemiology, pathogenicity, vaccines and diagnostics. Workshop Report from the European Commission (DG XII, INCO-DC) and the Joint United Nations Programme on HIV/AIDS. AIDS 1997; 11(15):17-36.
17. de Souza M, Song MS, Carr JK, et al.: HIV-1 subtypes A and B isolated from the Republic of Korea. AIDS 1997;11(3): 389-391.
18. Gao F, Robertson DL, Morrison SG, et al.: The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70(10):7013-7029.
19. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, and Rinaldo CR Jr: The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126(2):310-318.
20. Barkan SE, Melnick SL, Preston-Martin S, et al.: The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9(2):117-125.
21. Castro E, Lorenzana I, Moreno M, and Echeverria G: Highly conserved HIV-1 subtype B strains circulating in Honduras. The 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005.
22. Cleghorn FR, Jack N, Carr JK, et al.: A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc Natl Acad Sci USA 2000;97(19):10532-10537.
23. Vaughan HE, Cane P, Pillay D, and Tedder RS: Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. AIDS Res Hum Retroviruses 2003;19(10):929-932.
24. Pross HF and Maroun JA: The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 1984;68(1-2):235- 249.
25. Farzadegan H, Hoover DR, Astemborski J, et al.: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352(9139):1510-1514.
26. Evans JS, Nims T, Cooley J, et al.: Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997;175(4):795-800.
27. Junghans C, Ledergerber B, Chan P, Weber R, and Egger M: Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study. Lancet 1999;353(9152):589; author reply 590-591.
28. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, and Quinn TC: Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999;180(3):666-672.
29. Baum LL: Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep 2010;7(1):11-18.
30. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, and Baum LL: Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J Infect Dis 2002;185(4):439-447.
31. Forthal DN, Landucci G, and Keenan B: Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4 + lymphocyte count. AIDS Res Hum Retroviruses 2001;17(6):553-561.
32. Ahmad R, Sindhu ST, Toma E, et al.: Evidence for a correlation between antibody-dependent cellular cytotoxicitymediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001;21(3):227-233.
33. Alpert MD, Heyer LN, Williams DE, et al.: A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1-or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 2012;86(22):12039-12052.
34. Smalls-Mantey A, Doria-Rose N, Klein R, et al.: Antibodydependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012;86(16):8672-8680.
35. Sun Y, Asmal M, Lane S, et al.: Antibody-dependent cellmediated cytotoxicity in simian immunodeficiency virusinfected rhesus monkeys. J Virol 2011;85(14):6906-6912.
36. Gomez-Roman VR, Florese RH, Peng B, et al.: An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 2006;43(3):270-277.